observation
OtherNot applicable-Observational study
NCT Number: NCT05001087
The aim of this observational study is the creation of a national multiple myeloma registry to monitor the current routine clinical practice in Italy and describe the standard of care adopted for the diagnosis and treatment of patients with multiple myeloma in the different Italian hematology centers.
Interested in participating?
Request Info18 year and older
All sexes
Observational
A.O.U di Careggi, Florence, Firenze, Italy
In Italy, myeloma accounts for 1.3% of all tumour diagnoses in males and for 1.2% of all tumour diagnoses in women. The incidence is 9.5 new cases per 100,000 males and 8.1 cases per 100,000 females. Median age at diagnosis is 68 years and approximately 2% of patients experience onset before the age of 4011. Therefore is to establish a national disease registry to monitor current routine clinical practice in Italy and to describe the standard of care adopted for the diagnosis and treatment of patients with myeloma. National registries have already been established in some countries and a recently-published meta-analysis highlighted certain differences in treatment, survival and the demographic characteristics of patients. An Italian national registry is important for analysing the current situation, in order to deal with the changes that lie ahead. In addition to the standard epidemiological registry - as described in the statistical methods section - a patientpowered registry (PPR) will also be established to encourage patient participation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Not applicable-Observational study
Time frame: 3 years
Time between diagnosis and death.
Time frame: 3 years
Time to next treatment will be measured from the screening to the date of next anti-myeloma therapy, for each treatment regime.
Time frame: 3 years
Periodic completion of the EORTC-QLQ-C30 to evaluate the quality of life of the patients.
Time frame: 3 years
Evaluation of the costs incurred by the patients related to the therapy based on the different treatments.
Contact information is provided by the study sponsor or research team.
Fondazione EMN Italy Onlus
Other
A "Physician & Patient-powered" Cohort Registry
Acronym: MY MYELOMA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06500884
Blood Protein Disorders, Cardiovascular Diseases
San Francisco, California, United States
View Trial DetailsNCT06768489
Blood Protein Disorders, Cardiovascular Diseases
Clayton, Australia
View Trial DetailsNCT01676805
Blood Protein Disorders, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06152575
Blood Protein Disorders, Cardiovascular Diseases
Mobile, Alabama, United States
View Trial Details